Through grant funding and other forms of support from the Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), and the European Vaccines Hub for Pandemic Readiness (EVH), Dyadic International, Inc. (Nasdaq: DYAI) is working to accelerate the development of vaccines, monoclonal antibodies, and other biologic medicines while increasing manufacturing productivity and lowering production costs.
CEPI is a global partnership dedicated to accelerating the development of vaccines and other biologic countermeasures against epidemic and pandemic threats. EVH is a €170 million European consortium whose mission is to achieve and maintain the highest possible level of European Union pandemic readiness through an integrated network supporting the research and development of safe and effective vaccines and monoclonal antibodies.
These organizations are supporting Dyadic’s efforts to demonstrate how its proprietary C1 gene-expression platform may help overcome persistent limitations associated with traditional biologics development and manufacturing. The objective is to make essential medicines faster to develop, more productive to manufacture, and more affordable and sustainable to supply—helping prevent and treat diseases globally so that no one is left behind.
Enter Dyadic and its advanced fungal expression biotechnology.
Artificial intelligence is rapidly transforming the discovery and design of proteins, antibodies, enzymes, and other biomolecules. However, AI-designed DNA sequences must still be converted into real, functional products at commercially relevant speed, scale, and cost. Dyadic’s C1 and Dapibus protein-production platforms can help unlock the power of AI by providing the biological manufacturing engine capable of turning DNA designs into life-saving medicines, more nutritious foods and beverages, and enzymes supporting renewable fuels and other sustainable products.
Dyadic’s C1 platform is designed to help close the critical window between identifying an emerging infectious threat and making effective medical countermeasures available. Many legacy biologics-production systems can be slow, complex, expensive, and difficult to scale rapidly. These limitations can delay access to vaccines and treatments, particularly in low- and middle-income countries and in regions where local manufacturing capacity remains limited.
Using engineered fungal production systems, Dyadic is working to accelerate the development and manufacture of vaccine antigens, monoclonal antibodies, therapeutic proteins, enzymes, and other recombinant products. Its platforms combine rapid stable-cell-line development, short fermentation cycles, high levels of secreted protein production, low-cost chemically defined media, and scalability using conventional microbial fermentation infrastructure.
This approach may enable critical proteins to be produced more rapidly, in greater quantities, and at a lower cost than may be achievable with certain traditional manufacturing systems. It may also expand the number of facilities and geographic regions capable of manufacturing advanced biologic medicines, nutritional proteins, and industrial enzymes.
The implications for global health equity could be profound. When life-saving vaccines and treatments can be developed quickly, manufactured efficiently, and supplied affordably near the point of need, regional outbreaks are more likely to be contained before escalating into international crises. Faster and more economical manufacturing may also improve access to biologic medicines used to prevent or treat endemic infectious diseases and other serious health conditions.
Recent pandemics demonstrated that scientific discovery alone is not enough. The world also needs flexible, scalable, and economically sustainable manufacturing technologies capable of converting scientific and AI-enabled discoveries into accessible products. A vaccine, antibody, nutritional protein, or industrial enzyme can deliver value only if it can be produced at sufficient scale, acceptable quality, and an economically viable cost.
Dyadic’s work with leading global-health organizations underscores a vital path forward for biotechnology. Innovation in manufacturing can be just as important as innovation in discovery. By helping shorten development timelines, increase productivity, expand manufacturing flexibility, and reduce costs, Dyadic’s platforms could become important production tools for pandemic preparedness, routine healthcare, improved nutrition, renewable fuels, and a more sustainable global bioeconomy.
(Nasdaq:DYAI) Unlocking the power of AI and turning DNA into useful products through scalable, economical biotechnology may ultimately prove to be one of the world’s most effective tools for protecting health, improving nutrition, advancing sustainability, and ensuring that no one is left behind.
Leave a Reply